All In Biotech

Drug Trial Radar · NCT03552757

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,210

Actual

Start

Jun 4, 2018

Primary completion

Mar 24, 2020

Study completion May 1, 2020

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk of type 2 diabetes. Therefore, weight loss has shown to have a beneficial impact on the blood sugar levels. The participant will either get semaglutide or "dummy" medicine - which treatment the participant get is decided by chance. The participant will need to take 2 injections at the same time once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years

Conditions

  • Obesity
  • Overweight

Interventions

  • Semaglutide 1.0 mgDrug

    Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.

  • Semaglutide 2.4 mgDrug

    Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

  • Placebo I (Semaglutide)Drug

    S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

  • Placebo II (Semaglutide)Drug

    S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Body Weight (%) - Semaglutide 2.4 mg Versus PlaceboTime frame: Baseline (week 0) to week 68
  2. Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus PlaceboTime frame: At week 68

Locations

147 sites in 13 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Buena Park, California

  • Novo Nordisk Investigational Site

    Concord, California

  • Novo Nordisk Investigational Site

    Fresno, California

  • Novo Nordisk Investigational Site

    Lomita, California

  • Novo Nordisk Investigational Site

    Los Angeles, California

  • Novo Nordisk Investigational Site

    Mission Hills, California

  • Novo Nordisk Investigational Site

    Spring Valley, California

  • Novo Nordisk Investigational Site

    Tarzana, California

  • Novo Nordisk Investigational Site

    Golden, Colorado

  • Novo Nordisk Investigational Site

    Clearwater, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Kissimmee, Florida

  • Novo Nordisk Investigational Site

    St. Petersburg, Florida

  • Novo Nordisk Investigational Site

    Tampa, Florida

  • Novo Nordisk Investigational Site

    Alpharetta, Georgia

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Roswell, Georgia

  • Novo Nordisk Investigational Site

    Chicago, Illinois

  • Novo Nordisk Investigational Site

    Chicago, Illinois

  • Novo Nordisk Investigational Site

    Springfield, Illinois

  • Novo Nordisk Investigational Site

    West Des Moines, Iowa

  • Novo Nordisk Investigational Site

    Topeka, Kansas

  • Novo Nordisk Investigational Site

    Lexington, Kentucky

  • Novo Nordisk Investigational Site

    Louisville, Kentucky

  • Novo Nordisk Investigational Site

    Minneapolis, Minnesota

  • Novo Nordisk Investigational Site

    Olive Branch, Mississippi

  • Novo Nordisk Investigational Site

    Butte, Montana

  • Novo Nordisk Investigational Site

    Lawrenceville, New Jersey

  • Novo Nordisk Investigational Site

    Chapel Hill, North Carolina

  • Novo Nordisk Investigational Site

    Greensboro, North Carolina

  • Novo Nordisk Investigational Site

    Greenville, North Carolina

  • Novo Nordisk Investigational Site

    Hickory, North Carolina

  • Novo Nordisk Investigational Site

    Salisbury, North Carolina

  • Novo Nordisk Investigational Site

    Wilmington, North Carolina

  • Novo Nordisk Investigational Site

    Wadsworth, Ohio

  • Novo Nordisk Investigational Site

    Anderson, South Carolina

  • Novo Nordisk Investigational Site

    Mt. Pleasant, South Carolina

  • Novo Nordisk Investigational Site

    Bristol, Tennessee

  • Novo Nordisk Investigational Site

    Nashville, Tennessee

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.